{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-279630","form_type":"8-K/A","ticker":"SGMO","cik":"0001001233","company_name":"SANGAMO THERAPEUTICS, INC","filed_at":"2026-06-23T20:42:16+00:00","discovered_at":"2026-06-23T20:43:00.398668+00:00","generated_at":"2026-06-23T20:43:25.728985+00:00","sec_items":["9.01"],"event_type":"m_and_a","sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Sangamo files Ch 11, sells key capsid/gene therapy assets to Eli Lilly and Astellas","bullets":["Sangamo filed Chapter 11 bankruptcy and signed asset sale agreements with Eli Lilly and Astellas Gene Therapies.","Lilly's subsidiary is stalking horse bidder for capsids (STAC-150, STAC-BBB), SIFTER, MINT, and zinc finger prion assets.","Astellas acquires assets under separate agreement; terms not disclosed in this filing.","Sangamo common stock delisted from Nasdaq on May 5, 2026; now trading on OTCQB.","Sale subject to Bankruptcy Court approval and potential higher bids in auction process."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-279630","json":"https://secwatch.observer/filing/0001193125-26-279630.json","markdown":"https://secwatch.observer/filing/0001193125-26-279630.md","text":"https://secwatch.observer/filing/0001193125-26-279630.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1001233/000119312526279630/0001193125-26-279630-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1001233/000119312526279630/d68888d8ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T20:43:25.728985+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}